Pulse Biosciences Inc Common Stock (DE) (PLSE)
Stock · NASDAQ · Health Care
$44.36as of 10/16/2026
Price chart
Active signals
PLSE Signal Track Record
How signals performed across all stocks →What PLSE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +0.7% | 51% | September 16, 2026 |
| Bollinger Band Breakout | 33 | -5.1% | 42% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -11.2% | 27% | October 29, 2025 |
| Bollinger Band BreakdownActive now | 9 | +0.8% | 56% | October 2, 2026 |
| Any 20-session window (baseline) | +3.3% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System desi…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 116
- Website
- www.pulsebiosciences.com/
Fundamentals
- 1-day range
- $43.32$46.67
- Market cap
- $2.65B
- P/E (trailing)
- —
- P/E (forward)
- -37.97
- EPS (trailing)
- $-1.17
- Dividend yield
- —
- Beta
- 1.64
- Avg. volume
- 519.5K
How Pulse Biosciences Inc Common Stock (DE) Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Pulse Biosciences Inc Common Stock (DE) Competitors
Chosen by industry and closest market cap.
- PLSEPulse Biosciences Inc Common Stock (DE)$44.43▼ 2.54%Market cap $2.65BP/E —$12.56$58.9
- XRAYDENTSPLY SIRONA Inc. Common Stock$8.57▼ 2.94%Market cap $2.64BP/E —$8.38$14.76
- UFPTUFP Technologies Inc. Common Stock$291.67▼ 1.86%Market cap $2.41BP/E 31.50$173.86$338.71
- HTFLHeartflow Inc. Common Stock$48.29▼ 5.14%Market cap $2.34BP/E —$20.13$54.32
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- LMATLeMaitre Vascular Inc. Common Stock$80.82▼ 2.81%Market cap $1.85BP/E 29.17$78.22$118.01
- NVCRNovoCure Limited Ordinary Shares$14.07▼ 2.36%Market cap $1.83BP/E —$9.82$21.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLSE Pulse Biosciences Inc Common Stock (DE) | $2.65B | — | $44.43 | ▼ 2.54% | $12.56$58.9 |
| XRAY DENTSPLY SIRONA Inc. Common Stock | $2.64B | — | $8.57 | ▼ 2.94% | $8.38$14.76 |
| UFPT UFP Technologies Inc. Common Stock | $2.41B | 31.50 | $291.67 | ▼ 1.86% | $173.86$338.71 |
| HTFL Heartflow Inc. Common Stock | $2.34B | — | $48.29 | ▼ 5.14% | $20.13$54.32 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| LMAT LeMaitre Vascular Inc. Common Stock | $1.85B | 29.17 | $80.82 | ▼ 2.81% | $78.22$118.01 |
| NVCR NovoCure Limited Ordinary Shares | $1.83B | — | $14.07 | ▼ 2.36% | $9.82$21.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Floridabenzinga · 10/14/2026
- Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse SpotlightYahoo · 10/10/2026
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/9/2026
- Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026Yahoo · 10/8/2026
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation TreatmentYahoo · 10/7/2026
- Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58Benzinga · 10/6/2026
- Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA DataYahoo · 10/3/2026
- Pulse Biosciences: Promising Technology, But Hard To Justify Its ValuationSeekingAlpha · 9/27/2026
- TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On WednesdayBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Teplitsky Liane Rae · September 1, 2026 · Buy1.0K @ $49.95
- Teplitsky Liane Rae · August 31, 2026 · Buy1.0K @ $48.8
- Teplitsky Liane Rae · August 28, 2026 · Buy1.0K @ $48.35
- Teplitsky Liane Rae · August 26, 2026 · Buy1.0K @ $48.24
- Teplitsky Liane Rae · August 8, 2026 · Grant700.0K
- Teplitsky Liane Rae · August 8, 2026 · Grant200.0K
- Manmeet Singh Soni · June 11, 2026 · Grant30.0K
- Zanganeh Mahkam · June 11, 2026 · Grant14.5K
- Zanganeh Mahkam · June 11, 2026 · Grant30.0K
- Sainz Maria · June 11, 2026 · Grant3.8K
- Sainz Maria · June 11, 2026 · Grant30.0K
- van den Broek Richard · June 11, 2026 · Grant8.4K
- van den Broek Richard · June 11, 2026 · Grant30.0K
- Robert W. Duggan · June 11, 2026 · Grant12.5K
- Robert W. Duggan · June 11, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 7.49M
- Total value held
- $161.36M
- Institutional holders
- 89
- Unknown1.34M
- Unknown866.1K
- Unknown815.9K
- Unknown733.4K
- Unknown491.9K
- Unknown462.9K
- Unknown456.9K
- Unknown265.2K
- Unknown225.2K
- Unknown213.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.